Success Metrics

Clinical Success Rate
97.6%

Based on 40 completed trials

Completion Rate
98%(40/41)
Active Trials
0(0%)
Results Posted
83%(33 trials)
Terminated
1(2%)

Phase Distribution

Ph phase_2
17
41%
Ph not_applicable
2
5%
Ph phase_1
2
5%
Ph phase_4
5
12%
Ph phase_3
14
34%

Phase Distribution

2

Early Stage

17

Mid Stage

19

Late Stage

Phase Distribution40 total trials
Phase 1Safety & dosage
2(5.0%)
Phase 2Efficacy & side effects
17(42.5%)
Phase 3Large-scale testing
14(35.0%)
Phase 4Post-market surveillance
5(12.5%)
N/ANon-phased studies
2(5.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

97.6%

40 of 41 finished

Non-Completion Rate

2.4%

1 ended early

Currently Active

0

trials recruiting

Total Trials

41

all time

Status Distribution
Completed(40)
Terminated(1)

Detailed Status

Completed40
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
41
Active
0
Success Rate
97.6%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (5.0%)
Phase 217 (42.5%)
Phase 314 (35.0%)
Phase 45 (12.5%)
N/A2 (5.0%)

Trials by Status

terminated12%
completed4098%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT06602024Phase 3

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Completed
NCT03339713Phase 2

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

Completed
NCT03722589Phase 4

Immunogenicity Trial of Egg- Versus Non-Egg-Based Influenza Vaccines Among HCP

Completed
NCT02707692Not Applicable

Perturbing of HIV Reservoir With Immune Stimulation

Completed
NCT01711736Phase 3

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age

Completed
NCT01195779Phase 2

Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

Terminated
NCT00545025Phase 2

Revaccination With Influenza Vaccine GSK1247446A

Completed
NCT00540228Phase 2

Study to Evaluate an Influenza Vaccine Candidate

Completed
NCT00397215Phase 2

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age

Completed
NCT00385255Phase 3

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

Completed
NCT00502593Phase 2

Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children

Completed
NCT00377611Phase 4

Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™

Completed
NCT00453986Phase 3

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Completed
NCT01096056Phase 1

Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children

Completed
NCT01196026Phase 4

Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™

Completed
NCT00985790Phase 2

Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children

Completed
NCT01730378Phase 4

Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old

Completed
NCT00442975Phase 4

Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status

Completed
NCT00968890Phase 2

Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly

Completed
NCT00706563Phase 3

A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ / Influsplit SSW® 2008/2009 in Adults

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
41